2seventy bio, Inc. announced that Steven Bernstein, M.D. will join the company effective February 14, 2022 and assume the role of chief medical officer (CMO) and Susan Abu-Absi, Ph.D. has been appointed chief technology & manufacturing officer. Steven Bernstein, M.D., has more than 25 years of experience as a treating physician, translational scientist, and pharmaceutical executive. Prior to joining 2seventy, Dr. Bernstein served as Chief Translational Officer at Turnstone Biologics.

Before that, he served as Chair, Immuno-Oncology Translational Research and Development, and Head, Integrated Science, at Bristol-Myers Squibb (BMS). Susan Abu-Absi, Ph.D. has over 20 years of experience in biologics and cell & gene therapy process development and manufacturing. She most recently served as Senior Vice President and Head of Technical Development & Operations at 2seventy bio.

Previously, Susan led the oncology manufacturing organization at bluebird bio, having joined in 2017 as Head of Process and Analytical development and advancing through roles of increasing responsibility during her tenure.